{"url_path":"/sec/cpix/8-k/2026-09-11/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders","topic":"sec","document":{"doc_type":"8-K/A","doc_date":"2026-09-11","source_url":"https://www.sec.gov/Archives/edgar/data/1087294/0001087294-26-000068-index.html","accession_number":"0001087294-26-000068","cik":"0001087294","ticker":"CPIX","issuer_name":"CUMBERLAND PHARMACEUTICALS INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1087294/0001087294-26-000068-index.html","primary_entity_key":"0001087294","primary_entity_name":"CUMBERLAND PHARMACEUTICALS INC"},"word_count":176,"has_tables":true,"body_markdown":"Item 5.07    Submission of Matters to a Vote of Security Holders\n\nAt the 2026 Annual Meeting, the Company’s shareholders voted on, among other matters, an advisory proposal concerning the frequency of future advisory votes on compensation of the Company's named executive officers. As originally reported, the frequency of every three years received the highest number of shareholder votes. In light of such voting results, and after further discussion by the Board of Directors, the Board has determined that advisory votes on compensation of the Company's named executive officers will be held every three years, until the next required advisory vote on the frequency of future advisory votes on executive compensation. The Company is required to hold advisory votes on the frequency of future advisory votes on executive compensation every six years.\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\nCumberland Pharmaceuticals Inc.\n\nDated: September 11, 2026By:/s/ John Hamm\n\nJohn Hamm\n\nChief Financial Officer"}